Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Finished Goods: 2021-2023

Historic Finished Goods for Kiniksa Pharmaceuticals International (KNSA) over the last 3 years, with Dec 2023 value amounting to $12.9 million.

  • Kiniksa Pharmaceuticals International's Finished Goods fell 15.85% to $12.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was $12.9 million, marking a year-over-year decrease of 15.85%. This contributed to the annual value of $12.9 million for FY2023, which is 15.85% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Finished Goods stood at $12.9 million for FY2023, which was down 15.85% from $15.3 million recorded in FY2022.
  • Kiniksa Pharmaceuticals International's 5-year Finished Goods high stood at $15.3 million for FY2022, and its period low was $3.7 million during FY2021.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Finished Goods had a median value of $12.9 million in 2023 and averaged $10.6 million.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Finished Goods surged by 315.97% in 2022 and then dropped by 15.85% in 2023.
  • Yearly analysis of 3 years shows Kiniksa Pharmaceuticals International's Finished Goods stood at $3.7 million in 2021, then skyrocketed by 315.97% to $15.3 million in 2022, then decreased by 15.85% to $12.9 million in 2023.